GlycoMimetics, a clinical-stage biotech developing treatments for sickle cell episodes and AML, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to sell 4 million shares at $14 to $16 per share but postponed on November 8. The company's updated filing removed the original IPO terms. The Gaithersburg, MD-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol GLYC. GlycoMimetics initially filed confidentially on August 21, 2013. Jefferies and Barclays are the joint bookrunners on the deal.
